These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33645382)

  • 1. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging pathways for precision medicine in management of cholangiocarcinoma.
    Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
    Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
    Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
    Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.
    Baiocchi L; Sato K; Ekser B; Kennedy L; Francis H; Ceci L; Lenci I; Alvaro D; Franchitto A; Onori P; Gaudio E; Wu C; Chakraborty S; Glaser S; Alpini G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):365-375. PubMed ID: 33226854
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholangiocarcinoma: novel therapeutic targets.
    Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
    Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular pathways and targeted therapy in cholangiocarcinoma.
    Dabney RS; Khalife M; Shahid K; Phan AT
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma: investigations into pathway-targeted therapies.
    Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic challenges at the preclinical level for targeted drug development for
    Loilome W; Dokduang H; Suksawat M; Padthaisong S
    Expert Opin Investig Drugs; 2021 Sep; 30(9):985-1006. PubMed ID: 34292795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing models of cholangiocarcinoma to close the translational gap in cancer research.
    Waddell SH; Boulter L
    Expert Opin Investig Drugs; 2021 Apr; 30(4):439-450. PubMed ID: 33513027
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
    Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
    Sahin IH; Tan E; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
    Lodl E; Ramnaraign B; Sahin I; Wheeler S
    J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.